A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
Completed · Phase 2
Conditions studied: Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer, Uterine Cancer
In brief
The clinical trial was a companion study to protocol CL-PTL-119 (A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects with Stage IIIb-IV Ovarian Cancer in Clinical Complete Response following Surgery and Primary Chemotherapy (VITAL) NCT02346747). Participants who had investigational product (Vigil) successfully made but were not eligible to enroll onto the VITAL study or previously randomized to placebo were given the opportunity to participate in this protocol. The main goal of this clinical trial was to determine the safety of combining Vigil therapy with atezolizumab.
Key facts
- Study ID
- NCT03073525
- Run by
- Gradalis, Inc.
- People needed
- 25
- Starts
- 2017-05-31
- Expected to finish
- 2022-05-18
- Last updated by the study team
- 2023-04-05
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- University of South Alabama Mitchell Cancer Institute — Mobile, Alabama, United States
- Georgia Cancer Center at Augusta University — Augusta, Georgia, United States
- Henry Ford Hospital — Detroit, Michigan, United States
- Billings Clinic — Billings, Montana, United States
- Dartmouth-Hitchcock Medical Center/ Norris Cotton Cancer Center — Lebanon, New Hampshire, United States
- Prisma Health Cancer Institute — Greenville, South Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.